Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 370

The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.

Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25

Open access
Hay, Debbie L, Garelja, Michael L, Poyner, David R, Walker, Christopher S·2018·British Journal of Pharmacology

Abstract

The calcitonin/CGRP family of peptides includes calcitonin, α and β CGRP, amylin, adrenomedullin (AM) and adrenomedullin 2/intermedin (AM2/IMD). Their receptors consist of one of two GPCRs, the calcitonin receptor (CTR) or the calcitonin receptor‐like receptor (CLR). Further diversity arises from heterodimerization of these GPCRs with one of three receptor activity‐modifying proteins (RAMPs). This gives the CGRP receptor (CLR/RAMP1), the AM 1 and AM 2 receptors (CLR/RAMP2 or RAMP3) and the AMY 1,AMY 2 and AMY 3 receptors (CTR/RAMPs1–3 complexes, respectively). Apart from the CGRP receptor, there are only peptide antagonists widely available for these receptors, and these have limited selectivity, thus defining the function of each receptor in vivo remains challenging. Further challenges arise from the probable co‐expression of CTR with the CTR/RAMP complexes and species‐dependent splice variants of the CTR (CT(a)and CT(b)). Furthermore, the AMY 1(a)receptor is activated equally well by both amylin and CGRP, and the preferred receptor for AM2/IMD has been unclear. However, there are clear therapeutic rationales for developing agents against the various receptors for these peptides. For example, many agents targeting the CGRP system are in clinical trials, and pramlintide, an amylin analogue, is an approved therapy for insulin‐requiring diabetes. This review provides an update on the pharmacology of the calcitonin family of peptides by members of the corresponding subcommittee of the International Union of Basic and Clinical Pharmacology and colleagues.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.14075

Cites

107 of 107 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 370

Metadata

Authors
Hay, D. L., Garelja, M. L., Poyner, D. R., & Walker, C. S.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2017-11-28
Volume
175
Issue
1
Pages
3-17
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2765091532
Cited by
370
References
107
FWCI
14.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.